Azenta

AZTA

Market cap $1.61B

Azenta, Inc. ( AZTA ) Q4 2025 Earnings Call November 21, 2025 8:30 AM EST Company Participants Yvonne Perron - Vice President of Financial Planning & Analysis and Investor Relations John P. Marotta - President, CEO & Director Lawrence Lin - Executive VP & CFO Conference Call Participants David Saxon - Needham & Company, LLC, Research Division Steven Etoch - Stephens Inc., Research Division Andrew Cooper - Raymond James & Associates, Inc., Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Jacqueline Kisa - TD Cowen, Research Division Paul Knight - KeyBanc Capital Markets Inc., Research Division Presentation Operator Greetings, and welcome to the Azenta Q4 2025 Financial Results.

Q4'25 reported revenue growth of 6% year over year and 4% on an organic basis FY'25 reported revenue growth of 4% and 3% on an organic basis FY'25 Adjusted EBITDA margin expansion of 310 basis points versus last year FY'26 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis points BURLINGTON, Mass. , Nov. 21, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2025.

BURLINGTON, Mass. , Nov. 12, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2025 earnings which ended on September 30, 2025, on Friday, November 21, 2025, before the market opens.

BURLINGTON, Mass. , Nov. 4, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership with the PRECEDE Foundation, an international, multi-institutional collaborative focused on early detection and prevention of pancreatic cancer.

BURLINGTON, Mass. , Oct. 15, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it will host an Investor Day on Wednesday, December 10, 2025, at the Company's biorepository facility in Indianapolis, Indiana.

Azenta, Inc. (NASDAQ:AZTA ) Q3 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants John P. Marotta - President, CEO & Director Lawrence Y.

Azenta (AZTA) Q3 EPS Jumps 36%

BURLINGTON, Mass. , Aug. 5, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2025.

BURLINGTON, Mass. , July 31, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Care, and Nephronomics, a Renal Precision Medicine company, to begin genomic sequencing and data generation for Frenova's transformative MyReason® genomics research program.

Frenova and Nephronomics, a renal precision company co-founded by Fresenius Medical Care, initiate collaboration with GENEWIZ by Azenta Life Sciences Provides vital insights through sophisticated genomic sequencing and analysis of Frenova's My Reason® genomic and clinical data registry Paves way for advances in precision kidney disease care, novel therapies, and diagnostics BAD HOMBURG, Germany , July 31, 2025 /PRNewswire/ -- Fresenius Medical Care today announced that Frenova, the company's third-party clinical research organization, along with Nephronomics, a renal precision medicine company, and GENEWIZ by Azenta Life Sciences, have entered a collaboration to advance the genomic analysis efforts for Frenova's transformative My Reason® genomics research program. This strategic collaboration aims to leverage cutting-edge technologies to better understand kidney, cardiovascular, and metabolic diseases while driving advancements in precision medicine for patients worldwide.